Meghan Skinner
Primary Care · Searcy, ARNPI 1992150858
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,450 and has fallen 84.4% since, to $226 in 2024.
Across 202 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$708
- AbbVie$615
- Amgen$499
- Biogen$389
- UCB, Inc.$293
- Kyowa Kirin, Inc.$225
- plus $860 from 17 others
What the payments were for
- Food & beverage$3,589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 39 | $708 |
| AbbVie(2 entities) | 36 | $615 |
| Amgen | 24 | $499 |
| Biogen | 23 | $389 |
| UCB, Inc. | 14 | $293 |
| Kyowa Kirin, Inc. | 12 | $225 |
| Biohaven Pharmaceuticals, Inc. | 14 | $161 |
| AstraZeneca | 8 | $140 |
| SK Life Science, Inc. | 6 | $117 |
| Lilly USA, LLC | 5 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Tanabe Pharma America, Inc. | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Lundbeck LLC | 2 | $41 |
| Sanofi | 1 | $28 |
| Argenx US, Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| GE HealthCare | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Corium, LLC | 1 | $3 |
How this compares
$3,589 in reported general payments places this provider in the 85th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 18 | $12,405 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $108 |
Paid to pharmacies, not to this prescriber.
Other primary care in Searcy
- Andrew OliverMaumelle$45K
- Chelsea PressonLittle Rock$22K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
- Katherine ThompsonLittle Rock$10K
- Barbara ColeNorth Little Rock$9K
- Celeste WilliamsCenterton$6K
- Jennifer RogersCharleston$4K
- Krystalyn WilliamsLittle Rock$3K
- Sharon ArnoldBatesville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.